Trending: Lilly's Kisunla Gets FDA Approval to Treat Early Symptomatic Alzheimer's
14:15 ET -- Eli Lilly is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. The U.S. Food and Drug Administration approved Lilly's Kisunla once-monthly infusion as a treatment for Alzheimer's disease in adults with early symptomatic disease, including those with mild cognitive impairment as well as some forms of mild dementia. The pharmaceutical giant said Kisunla slowed cognitive and functional decline by up to 35% versus placebo at 18 months in its phase 3 study and reduced participants' risk of progressing to the next clinical stage of disease by up to 39%. Kisunla will cost about $12,522 for six months of treatment, Lilly said. Dow Jones & Co. owns Factiva. (jennifer.tershak@wsj.com)
(END) Dow Jones Newswires
July 02, 2024 14:30 ET (18:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations